Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma

Will an immune checkpoint inhibitor plus chemotherapy improve 5-year overall survival as first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC)?In this secondary analysis of a randomized clinical trial including 263 randomized patients, the addition of camrelizumab to chemotherapy was associated with a statistically significant and clinically meaningful improvement in 5-year overall survival compared with chemotherapy alone. Rapid clearance of plasma Epstein-Barr virus DNA emerged as a valuable prognostic biomarker of long-term survival.These findings provide the first 5-year evidence to inform clinical practice on programmed cell death 1 protein–based chemoimmunotherapy in RM-NPC, supporting camrelizumab plus chemotherapy as the standard first-line treatment and establishing a new benchmark for long-term survival in this population.

Corresponding Author: Li Zhang, MD (zhangli@sysucc.org.cn), and Yunpeng Yang, MD (yangyp@sysucc.org.cn), Sun Yat-sen University Cancer Center, No.651 E Dongfeng Rd, Guangzhou, 510060, China.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.